Open in interactive viewer → charts, metric popovers & call review

Jenoptik Posts a 37% Semi Margin, Then Asks You Not to Believe It

A blowout order book, a raised profit guide and a 1.1x leverage ratio — all pointing at a December Capital Markets Day that management is using as a rain check on nearly every other question
JEN.DE · Earnings Call · 2026-11-09

The Upgrade Nobody Was Allowed to Extrapolate

Jenoptik's Q3 was, on the face of it, the print that re-rates a mid-cap industrial. Group order intake rose more than 40% year-on-year, pushing the order backlog to a bit north of EUR 900 million and the nine-month book-to-bill to roughly 1.4. Revenue finally caught up with the order book — Q3 up around 18%, the first nine months up almost 7%. EBITDA reached roughly EUR 178 million, up a little over 35%, lifting the margin by about 470 basis points; EBIT rose almost 59% to a 14.4% margin and earnings per share climbed 60% to EUR 1.28. Management then raised full-year EBITDA margin guidance to around 22% from a prior 20%–21%.

And then, unusually, CEO Dominic Dorfner and CFO Prisca Havranek-Kosicek spent much of the call telling investors not to annualise any of it. The Semi & Advanced Manufacturing unit ran a ~34% margin for the nine months and something closer to 37% in Q3 alone — a level above prior cycle peaks in a business that has historically been talked about as a 30%-ish margin asset. The CFO was blunt: “Please don't extrapolate this margin level into the upcoming quarters. This would be too much.” — Prisca Havranek-Kosicek, CFO · 2026-11-09 The explanation is not pricing or a disguised one-off but the interaction of a lower post-restructuring cost base, a favourable product mix in a highly concentrated customer set, and the ramp of higher contribution from Dresden: “in Q3, literally everything was going right, and things were firing on all cylinders.” — Prisca Havranek-Kosicek, CFO · 2026-11-09

This is internally consistent rather than evasive. On the August call, analyst Lasse Stueben had probed the same semi margin and got the same hedge — that if semi fires on all cylinders, Jenoptik “can also land a tad above the, let's say, the 30% range that we round about, have sort of put out there.” — Prisca Havranek-Kosicek, CEO · 2026-08-12 What did change is the volition: last quarter the CFO cautioned that the record semi order levels could not necessarily be repeated; this quarter semi order intake exceeded the already-elevated first half. Management's caution has been overtaken by its own order book two quarters running.

What Is Genuinely New: A New CEO, a Pulled-Forward CMD, and a 2027 Revenue Base

The genuinely new items are structural, not cyclical. First, the leadership change is now visible in the transcript itself — Prisca Havranek-Kosicek, who fronted the August Q&A as CEO, now sits as CFO beside new CEO Dominic Dorfner, who opened this call. Second, the strategy review that was trailed in August as landing at the earliest at the end of this year, with any Capital Markets Day only “at some point over the course of next year” — Prisca Havranek-Kosicek, CEO · 2026-08-12, has been pulled forward: the CMD is now set for December 3 in Dresden. That compression matters — it means the new team is ready to talk capital allocation well ahead of when the market expected to hear it.

Third, and most under-appreciated, is duration. Asked whether customer conversations support the view that the semi upturn extends beyond 2027, Dorfner did not hedge: “We do see a strong demand in 2027 and beyond for our major semiconductor equipment customers in the lithography and also in the inspection space.” — Dominic Dorfner, CEO · 2026-11-09 He went further than most semi-cap executives will, saying there are no signals that changes in 2027–28 and that the company remains positive on 2029–30. Combined with the disclosure that only 30%–35% of the order book converts to 2026 revenue, the vast majority of that EUR 900 million-plus backlog is already a 2027 revenue base. The 2026 story is capacity expansion and execution; the 2027 story is already contracted.

The Soft Bits Buried in the Good News

Two things were downgraded while the headline was upgraded, and both were answered with the same brush-off. CapEx guidance was cut for the year — previously a slight decline versus 2025, now a lower level — because work on the high-precision clean room expansion at Jena is slipping, with go-live still targeted for end-2027. Given the whole equity case now rests on semi inspection output capacity, a capex cut in the middle of a ramp deserves more scrutiny than it received. Separately, Jenoptik took a mid-single-digit euro-million impairment on HOMMEL and flagged a review of its automotive-related assets, with the European automotive market still described as difficult. This is the second consecutive quarter in which automotive was framed as a demand problem rather than a timing problem.

Then there is Prodomax, the North American automotive automation asset. The divestiture intent was reiterated — “we want to divest this business, but we are not able to give you a timeline right now” — Prisca Havranek-Kosicek, CFO · 2026-11-09 — which is nearly word-for-word what management said in August: “nothing has changed on the strategic intent to divest this business over the course of time.” — Prisca Havranek-Kosicek, CEO · 2026-08-12 Two quarters, no progress, and the operating commentary has shifted only from "encouraging" to "cautiously positive." It sits in the corporate/other line, which swung roughly EUR 13 million negative year-on-year.

Confluence and Contradiction: What the Tape Says About the Order Book

The most interesting tension is external. Jenoptik is reporting an order inflection exactly as the public-market semi-cap complex has been de-rating. The global theme tape shows semi cap equipment down roughly 22% over 30 days across three names, High Bandwidth Memory down nearly 28% across fourteen, co packaged optics down 29% across fourteen, and data center capacity down 33% across a dozen tickers. Jenoptik is, in other words, riding a wave the market has begun to sell — a rare case where the fundamental order data and the price tape are pointed in opposite directions. Its exposure to the frothiest slice of that complex, optical data communications, is deliberately small — a low-double-digit euro-million revenue business — and management again deferred sizing its growth to the CMD.

The other confluence is defence. Defense optics — infrared cameras and laser rangefinders — is what is holding Biophotonics together against a tough dental and medtech base, keeping that unit at a ~23% nine-month margin with only moderate full-year growth expected. Management explicitly warned that the order pattern in a concentrated key-account business is volatile and should not be extrapolated, a caution worth carrying into any 2027 model.

The through-line is simple: this is a company whose operating leverage is genuinely inflecting, whose balance sheet has de-risked to 1.1x net debt/EBITDA from 1.6x, and whose CEO is choosing to spend the surplus — and the explanation for it — on December 3 rather than on this call. That is a deferral, not an answer. Investors now own a December option on capital allocation, Jena capacity, Prodomax and the datacom optionality, priced against a semi order book that has beaten management's own guidance three quarters running.